HR1563-119

Introduced

To amend the Controlled Substances Act to clarify that the possession, sale, purchase, importation, exportation, or transportation of drug testing equipment that tests for the presence of fentanyl or xylazine is not unlawful.

119th Congress Introduced Feb 25, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This bill, To amend the Controlled Substances Act to clarify that the possession, sale, purchase, importation, exportation, or transportation of drug testing equipment that tests for the presence of fentanyl or xylazine is not unlawful., changes federal law or congressional policy affecting transportation operators and travelers. The main policy domain is Transportation, Trade, Healthcare.

Who Benefits and How

transportation operators and travelers may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.

Who Bears the Burden and How

federal implementing agencies, transportation operators and travelers may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.

Key Provisions

  • Section HAB6E54FD911048FE8DF99386509918FC: 1. Short title This Act may be cited as the Safeguarding Testing and Overdose Prevention Against Fentanyl and Xylazine Act or the STOP Fentanyl and Xylazine...
  • Section HCA8F2F015C9D4078BD96143844D44A9E: 2. Clarification regarding the treatment of equipment that indicates the presence of fentanyl or xylazine in a compound Section 422 of the Controlled...

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

This bill, To amend the Controlled Substances Act to clarify that the possession, sale, purchase, importation, exportation, or transportation of drug testing equipment that tests for the presence of fentanyl or xylazine is not unlawful., changes federal law or congressional policy affecting transportation operators and travelers.

Key Policy Areas

Transportation, Trade, Healthcare

Primary Purpose

This bill, To amend the Controlled Substances Act to clarify that the possession, sale, purchase, importation, exportation, or transportation of drug testing equipment that tests for the presence of fentanyl or xylazine is not unlawful., changes federal law or congressional policy affecting transportation operators and travelers.

Policy Domains

Transportation Trade Healthcare

Whole bill

Identified Gains
  • transportation operators and travelers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
transportation operators and travelers:
Identified Costs
  • federal implementing agencies
  • transportation operators and travelers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
federal implementing agencies:
transportation operators and travelers:

Legislative Progress

Introduced
Introduced Committee Passed
Feb 25, 2025

Ms. Crockett (for herself and Mr. Gooden) introduced the following …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Transportation Trade Healthcare
Actor Mappings
"federal_implementing_agencies"
→ Federal agencies assigned duties by the bill

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology